RomondEHPerezEABryantJ. Trastuzumab plus adjuvant chemotherapy for operable her2-positive breast cancer. N Engl J Med2005; 353: 1673–1684.
3.
Piccart-GebhartMJProcterMLeyland-JonesB. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med2005; 353: 1659–1672.
4.
JoensuuHKellokumpu-LehtinenPBonoP. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med2006; 354: 809–820.
5.
PerezEARomondEHSumanVJ. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol2011; 29: 3366–3373.
6.
SlamonDEiermannWRobertN. Adjuvant trastuzumab in her2-positive breast cancer. N Engl J Med2011; 365: 1273–1283.
7.
HarrisCAWardRLDobbinsTA. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol2011; 22: 1308–1317.
8.
PegramMDLiptonAHayesDF. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185her2/neu monoclonal antibody plus cisplatin in patients with her2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol1998; 16: 2659–2671.
9.
CobleighMAVogelCLTripathyD. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol1999; 17: 2639–2648.
10.
Leyland-JonesBGelmonKAyoubJ. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol2003; 21: 3965–3971.
11.
BaselgaJCarbonellXCastaneda-SotoN. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol2005; 23: 2162–2171.
12.
BaselgaJTripathyDMendelsohnJ. Phase II study of weekly intravenous recombinant humanized anti-p185her2 monoclonal antibody in patients with her2/neu-overexpressing metastatic breast cancer. J Clin Oncol1996; 14: 737–744.
13.
TokudaYOhnishiYShimamuraK. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer1996; 73: 1362–1365.
14.
PegramMDSlamonDJ. Combination therapy with trastuzumab (HERCEPTIN®) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Sem Oncol1999; 26(4 Suppl 12): 89–95.
15.
FeliciADi SegniMContestabileB. Dose scheduling and pharmacokinetic (pk) study of trastuzumab in patients (pts) with her2/neu overexpressing breast cancer?J Clin Oncol2007; 25: 1109–1109.
16.
CarterPPrestaLGormanCM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA1992; 89: 4285–4289.
HarrisKAWashingtonCBLiebermanG. A population pharmacokinetic (pk) model for trastuzumab (herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol2002; 21: abstr 488–abstr 488.
